Mankind Pharma Ltd

Mankind Pharma Ltd Share Price Today: Live Updates & Key Insights

Get insights on Mankind Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Mankind Pharma Ltd Share Price Chart

Mankind Pharma Ltd Fundamentals

Traded Volume: 2,58,243

Market Cap(Cr): 92,425

Avg Traded Price 59.53

1 Year return -13.23%

Upper Circuit 2,274

Lower Circuit 2,224.1

P/E TTM 53.00

P/B Ratio 42.00

Traded Value(Cr) 5782.58

EPS TTM 42.418

Book value 42.418

Dividend Yield 1Y 0.04%

Mankind Pharma Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Mankind Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Mankind Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +0.72%

1M -7.34%

3M -10.50%

1Y -13.23%

YTD -21.59%

Mankind Pharma Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Mankind Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 5.92L

Day Before Yesterday 2.94L

1W Avg 6.94L

1M Avg 5.41L

3M Avg 4.01L

Mankind Pharma Ltd Technical Details

Mankind Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 2235

Support 2 2211

Support 3 2178

Pivot Point : 2268

Resistance 1 2292

Resistance 2 2324

Resistance 3 2348

Mankind Pharma Ltd Corporate Actions

Mankind Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Mankind Pharma Ltd’s capital allocation strategies.

All

Ex-Date 08-Aug-2025 Type D Description 1.00/share@100.00% Record Date 08-Aug-2025 Ratio 100.00

Dividends

Announcement Date 08-Aug-2025 Ex Dividend Date 08-Aug-2025 Dividend(%) 100

Bonus

No Bonus has been declared by MANKIND

Splits

No Split has been declared by MANKIND

Others

Rights No Rights has been declared by MANKIND

Mankind Pharma Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Mankind Pharma Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Mankind Pharma Ltd's relative performance and valuation against major competitors.

Stock Name Dr Reddys Laboratories Ltd ₹1244.90 (-0.25%) M. Cap (Cr) 1039.02 1 Yr Return (%) +3.00% P/E (TTM) 18.01 PB Ratio 3.10

Stock Name Zydus Lifesciences Ltd ₹935.10 (-0.58%) M. Cap (Cr) 940.93 1 Yr Return (%) -1.88% P/E (TTM) 19.14 PB Ratio 3.93

Stock Name Lupin Ltd ₹2075.00 (+0.16%) M. Cap (Cr) 947.78 1 Yr Return (%) +1.92% P/E (TTM) 21.91 PB Ratio 5.51

Stock Name Mankind Pharma Ltd ₹2239.20 (-0.87%) M. Cap (Cr) 924.25 1 Yr Return (%) -13.23% P/E (TTM) 52.81 PB Ratio 6.45

Stock Name Aurobindo Pharma Ltd ₹1231.90 (+0.37%) M. Cap (Cr) 715.49 1 Yr Return (%) +0.36% P/E (TTM) 20.87 PB Ratio 2.19

Stock Name Alkem Laboratories Ltd ₹5686.50 (-1.50%) M. Cap (Cr) 679.91 1 Yr Return (%) +3.69% P/E (TTM) 28.90 PB Ratio 5.69

Stock Name Abbott India Ltd ₹29575.00 (-1.50%) M. Cap (Cr) 628.47 1 Yr Return (%) +7.53% P/E (TTM) 41.60 PB Ratio 14.83

Mankind Pharma Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Mankind Pharma Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 2322.16 Mar 2024 1982.97 Mar 2023 1798.99 Mar 2022 812.29 Mar 2021 1022.33

PARTICULARS Investing Activities Mar 2025 -12114.70 Mar 2024 -1919.12 Mar 2023 -1040.61 Mar 2022 -1369.34 Mar 2021 -1127.16

PARTICULARS Financing Activities Mar 2025 9845.34 Mar 2024 -8.68 Mar 2023 -710.41 Mar 2022 578.92 Mar 2021 88.87

PARTICULARS Net Cash Flow Mar 2025 -11.33 Mar 2024 55.07 Mar 2023 47.96 Mar 2022 21.87 Mar 2021 -15.96

Mankind Pharma Ltd Shareholding Pattern

This shows the ownership breakdown of Mankind Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 72.67%

Public 2.57%

Other Institutions 4.13%

FII 12.83%

Mutual Funds 7.78%

About Mankind Pharma Ltd

Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to Mankind Pharma Limited and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of `Lubistar Eye Drops' and `Tobastar Eye Drops'. In 2007, the Company diversified into the consumer healthcare segment with the launch of `Manforce' brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineralsupplements and anti-acne preparations categories. It entered into the business of animal healthcare segment and launched `Bandykind' and `Ceftiforce'. It established their Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh in year 2009. It launched the brand, `Preganews' into the consumer healthcare segment in year, 2010. In 2012, it set up their first R&D centre at IMT Manesar, in Haryana. Thereafter, in year 2014, the Company acquired Shree Jee Laboratory Private Limited along with its API manufacturing site at Behror, Rajasthan. It set up the Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh. In 2015, subsidiaries like Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore were formed into with the Company.In 2017, a new manufacturing facility got established in Sikkim.In 2019, the Company entered into female infertility business segment and launched `Dydroboon' tablets.In 2020, a subsidiary, Lifestar Pharmaceuticals Private Limited was formed in Nepal. The Company introduced a specialty therapeutic division for cardiovascular diseases (CVD) drugs segment and launched `Cilaheart' tablets and `Statpure' tablets in the market. It launched `Zukanorm' tablets for diabetes pharmaceuticals segment.Another new subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE got incorporated during the year 2021. It launched `Mlife' tablets in the specialty division for therapeutic respiratory pharmaceuticals. It entered into specialty therapeutic neuro/central nervous system pharmaceuticals segment business with the launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets.In 2022, the Company acquired formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited. Further, it entered into the transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets. It entered into the business of oncology segment with the launch of injection `Pacliall'. It acquired `Daffy' and `Combihale' brands from Dr. Reddy's Laboratories. The Company operate 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022. Their formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022.In April 2023, Company made an Initial Public Offer of 40,058,844 Equity Shares by raising funds aggregating to Rs 4326.35 Crore through Offer for Sale.During the FY 2022-23, the Company acquired 90% shareholding of Upakarma Ayurveda Private Limited, pursuant to which Upakarma Ayurveda became a step down subsidiary of the Company. Further, it also acquired 100% shareholding of Mankind Agritech Private Limited, making Mankind Agritech a wholly owned subsidiary of the Company. The Company also acquired minority stake of 6.30% in Actimed Therapeutics Limited.The erstwhile wholly owned subsidiaries, Lifestar Pharma Private Limited and Magnet Labs Private Limited got amalgamated with the Company and the Scheme of Amalgamation became effective from March 30, 2023. During the FY 2023-24, Mankind Medicare Private Limited was incorporated as the wholly owned subsidiary of the Company. The Company sold the Over the Counter (OTC) business of the Company to Mankind Consumer Products Private Limited, Wholly Owned Subsidiary Company as a going concern via slump sale on April 2, 2024. On October 23, 2024, Company acquired a 100% stake in Bharat Serums and Vaccines Limited (BSV), making it a wholly owned subsidiary of the Company. Urology Specialty Division launched in FY 2025.

Chairman & Wholetime Director

RAMESH CHAND JUNEJA

Registered office 208 Okhla Industrial Estate, Phase-III, New Delhi, New Delhi, 110020

FAX :91-11-47476600

Background

Incorporation Year 1991

Face Value ₹1.00

Market Lot 1

Mankind Pharma Ltd Latest News

VIEW MORE NEWS

FAQs on Mankind Pharma Ltd